Literature DB >> 23730944

A discrete choice experiment to determine patient preferences for injection devices in multiple sclerosis.

S L Shingler1, P Swinburn, S Ali, R Perard, A J Lloyd.   

Abstract

OBJECTIVE: Relapsing-remitting multiple sclerosis (MS) is usually managed with disease modifying drugs (DMDs), most commonly administered via self-injection. The aim of this study was to estimate the influence that different treatment-related attributes have for MS patients on their choice of MS DMD device. By establishing the relative importance of these characteristics for patients it should be possible to better understand the acceptability of a given device and to optimize the development of future devices.
METHODS: A discrete choice experiment (DCE) survey was developed on the basis of a review of published literature. Attributes identified for inclusion in the survey were: ease of use; comfort of use; presence of additional functions, needle visibility; practicality and efficacy. Choice sets were presented as pairs of hypothetical treatments based upon a fractional factorial design. One-hundred device-using MS patients completed the survey online. Analysis was conducted using a mixed-logit approach.
RESULTS: Analysis of the DCE data revealed that all attributes significantly predicted treatment choice. Efficacy exhibited the largest effect on treatment selection and this provided context for understanding the magnitude of impact for the other attributes. Reducing the discomfort associated with device use and eliminating the necessity for assembly or drug reconstitution were highly valued. The addition of reminder and time-stamping functions, improved needlestick injury prevention, and reduction in device size were secondary concerns but still deemed desirable.
CONCLUSION: Efficacy is of primary importance to MS patients, but characteristics of drug delivery devices can play an important role in treatment decision-making. Not all device characteristics could be included, and results are based upon 100 participants only. Findings suggest there is significant potential value in developing self-injection devices that are not only efficacious but also convenient and comfortable to use. Reducing barriers to adherence could potentially translate into improved treatment outcomes for patients with MS.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23730944     DOI: 10.3111/13696998.2013.811079

Source DB:  PubMed          Journal:  J Med Econ        ISSN: 1369-6998            Impact factor:   2.448


  17 in total

1.  A Systematic Review of Discrete-Choice Experiments and Conjoint Analysis Studies in People with Multiple Sclerosis.

Authors:  Edward J D Webb; David Meads; Ieva Eskyte; Natalie King; Naila Dracup; Jeremy Chataway; Helen L Ford; Joachim Marti; Sue H Pavitt; Klaus Schmierer; Ana Manzano
Journal:  Patient       Date:  2018-08       Impact factor: 3.883

2.  Preferences for Multiple Sclerosis Treatments: Using a Discrete-Choice Experiment to Examine Differences Across Subgroups of US Patients.

Authors:  Carol Mansfield; Nina Thomas; David Gebben; Maria Lucas; A Brett Hauber
Journal:  Int J MS Care       Date:  2017 Jul-Aug

3.  Quality of life and patient preferences: identification of subgroups of multiple sclerosis patients.

Authors:  Rosalba Rosato; Silvia Testa; Alessandra Oggero; Giorgia Molinengo; Antonio Bertolotto
Journal:  Qual Life Res       Date:  2015-02-26       Impact factor: 4.147

4.  Patient Preference for Self-Injection Devices in Rheumatoid Arthritis: A Discrete Choice Experiment in China.

Authors:  Yan Wei; Jin Zhao; Jian Ming; Xuewu Zhang; Yingyao Chen
Journal:  Patient Prefer Adherence       Date:  2022-08-31       Impact factor: 2.314

5.  Assessing the Value of Treatment to Address Various Symptoms Associated with Multiple Sclerosis: Results from a Contingent Valuation Study.

Authors:  Pei-Jung Lin; Cayla J Saret; Peter J Neumann; Eileen A Sandberg; Joshua T Cohen
Journal:  Pharmacoeconomics       Date:  2016-12       Impact factor: 4.981

6.  A discrete-choice experiment to determine patient preferences for injectable multiple sclerosis treatments in Germany.

Authors:  Christine Poulos; Elizabeth Kinter; Jui-Chen Yang; John F P Bridges; Joshua Posner; Erika Gleißner; Axel Mühlbacher; Bernd Kieseier
Journal:  Ther Adv Neurol Disord       Date:  2016-01-08       Impact factor: 6.570

7.  The Patient Perspective: Putting the Patient at the Center of the Translational Innovation Process.

Authors:  Leslie Wilson; Lawrence Lin; Kuldev Singh
Journal:  Clin Pharmacol Ther       Date:  2019-11-23       Impact factor: 6.903

8.  Preferred features of oral treatments and predictors of non-adherence: two web-based choice experiments in multiple sclerosis patients.

Authors:  Paul Wicks; David Brandes; Jinhee Park; Dimitri Liakhovitski; Tatiana Koudinova; Rahul Sasane
Journal:  Interact J Med Res       Date:  2015-03-05

9.  Patient preferences for treatment of multiple sclerosis with disease-modifying therapies: a discrete choice experiment.

Authors:  José Manuel Garcia-Dominguez; Delicias Muñoz; Marta Comellas; Irmina Gonzalbo; Luis Lizán; Carlos Polanco Sánchez
Journal:  Patient Prefer Adherence       Date:  2016-09-26       Impact factor: 2.711

Review 10.  Preference for pharmaceutical formulation and treatment process attributes.

Authors:  Katie D Stewart; Joseph A Johnston; Louis S Matza; Sarah E Curtis; Henry A Havel; Stephanie A Sweetana; Heather L Gelhorn
Journal:  Patient Prefer Adherence       Date:  2016-07-27       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.